Bio-Path (BPTH) Stock Price, News & Analysis

Company Overview

Bio-Path Holdings, Inc. (NASDAQ:BPTH) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for cancer and other serious diseases. The company’s platform centers on its proprietary Liposomal DNA Antisense Technology (LDAT), which leverages liposome-based delivery to transport antisense DNA molecules directly into targeted cells. By silencing specific messenger RNAs (mRNAs) associated with disease, Bio-Path aims to modulate pathways that drive tumor growth and survival.

The company’s lead investigational therapy, prexigebersen (BP1001), is designed to inhibit Grb2 mRNA, a critical adaptor protein involved in multiple oncogenic signaling pathways. Prexigebersen has been evaluated in early- and mid-stage clinical trials in patients with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and select solid tumors. In addition to prexigebersen, Bio-Path’s pipeline includes BP1002, an antisense candidate targeting BCL-2 mRNA to promote cancer cell apoptosis, and other preclinical programs exploring additional oncogenic targets.

Bio-Path conducts its clinical studies primarily in the United States, collaborating with major cancer centers to evaluate safety, pharmacokinetics, and preliminary efficacy across hematologic and solid tumor indications. The company aims to advance its most promising candidates through pivotal trials and regulatory filings, either independently or via strategic partnerships, to bring new treatment options to patients with high unmet medical needs.

Headquartered in Houston, Texas, Bio-Path is led by Founder, Chairman and Chief Executive Officer Francisco J. Hernandez, who brings extensive experience in biopharmaceutical research and development. The management team combines scientific expertise and clinical development know-how to drive the company’s translational programs from the laboratory into the clinic. Bio-Path continues to leverage its LDAT platform to expand its pipeline and explore novel applications of antisense technology in oncology and beyond.

Key Stats

• Today's Range: $0.06 to $0.07
• 50-Day Range: $0.07 to $0.17
• 52-Week Range: $0.06 to $3.39
• Volume: 229,730 shs
• Average Volume: 177,133 shs
• Market Capitalization: $521.74 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bio-Path Stock Analysis - MarketRank™

Bio-Path scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bio-Path.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bio-Path are expected to grow in the coming year, from ($3.34) to ($1.55) per share.

Price to Book Value per Share Ratio

Bio-Path has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.37% of the float of Bio-Path has been sold short.

Short Interest Ratio / Days to Cover

Bio-Path has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Path has recently increased by 46.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bio-Path does not currently pay a dividend.

Dividend Growth

Bio-Path does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.37% of the float of Bio-Path has been sold short.

Short Interest Ratio / Days to Cover

Bio-Path has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Path has recently increased by 46.90%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Bio-Path has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Bio-Path this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added Bio-Path to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Path insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.72% of the stock of Bio-Path is held by insiders.

Percentage Held by Institutions

Only 5.74% of the stock of Bio-Path is held by institutions.

BPTH Stock Analysis - Frequently Asked Questions

How have BPTH shares performed this year?

Bio-Path's stock was trading at $1.16 at the start of the year. Since then, BPTH stock has decreased by 94.6% and is now trading at $0.0628.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($1.16) EPS for the quarter, beating analysts' consensus estimates of ($1.54) by $0.38.
Read the conference call transcript.

When did Bio-Path's stock split?

Shares of Bio-Path reverse split on Friday, February 23rd 2024.The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), Micron Technology (MU), Anavex Life Sciences (AVXL) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 9/12/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BPTH
• CIK: 1133818
• Web: www.biopathholdings.com
• Phone: (832) 742-1357
• Fax: N/A
• Employees: 10
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,842.40%
• Return on Assets: -337.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.86
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 8,308,000
• Free Float: 5,726,000
• Market Cap: $556.64 thousand
• Optionable: Optionable
• Beta: -0.03